Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. LivaNova launches next-gen ICD, CRT-Ds in US
LivaNova said today it is launching its next-gen Platinium implantable cardiac defibrillators and cardiac resynchronization therapy devices in the U.S.
The next-gen devices include improved longevity and lower energy consumption, with service life projected over 14 years for single-chamber ICDs, 13 years for dual-chamber ICDs and 10 years for CRT-D devices, LivaNova said. Read more
4. Report: Big data, AI hold “greatest promise” for healthcare tech
Big data and artificial intelligence will have the greatest impact in the health-tech industry in the year ahead, according to a survey released yesterday.
The survey, performed by Silicon Valley Bank, polled 122 founders, execs and investors in health care technology companies about the biggest challenges, most promising technology and biggest growth sectors in the industry for the coming year. Read more
3. BD invests $100m in Nebraska manufacturing plant expansion
Becton Dickinson & Co. said today it is investing $100 into expanding its Holdrege, Neb.-based facility to make extra room for insulin syringe manufacturing operations.
The investment will support new manufacturing equipment and tech to expand production for BD insulin syringes, the Franklin Lakes, N.J.-based company said. BD currently produces more than 2 billion insulin syringes per year. Read more
2. Canon buys $40m stake in T2 Biosystems
Canon U.S.A. said today it made a $40 million dollar equity investment into diagnostic developer T2 Biosystems Inc., giving Canon a 19.9% stake.
Canon said it purchased approximately $40 million of T2’s stock at $6.56 per share through a private placement. Read more
1. Mylan CEO testifies before Senate about EpiPen pricing
Mylan CEO Heather Bresch testified before Senate yesterday after the Oversight and Government Reform Committee expressed concerns about the company’s price increases of its epinephrine auto-injector.
Since Mylan acquired the EpiPen from Merck in 2007 it has raised the price 17 times, from $100 in 2008 to nearly $600 today – a price increase of 548%. Read more
The post MassDevice.com +5 | The top 5 medtech stories for September 22, 2016 appeared first on MassDevice.
from MassDevice http://ift.tt/2cOSwjR
Cap comentari:
Publica un comentari a l'entrada